Carna Biosciences is building an internal drug pipeline through the application of our key technologies. We have successfully applied our proprietary kinase selectivity profiling, QuickScout® to generate novel, potent and selective lead compounds within a few months for many kinase targets. We are taking a rational approach to optimize a lead compound into drug candidates using X-ray co-crystallography information and computer-aided drug design. Our strategy for the further development of kinase inhibitors is to profile compounds against a panel of more than 270 kinases, and we believe this approach lead to a better understanding of structure-activity relationships, helping to avoid targets with toxicity and to select better drug candidates.
